Astria Therapeutics (ATXS)

• Market cap: $739M
• 1 day: -0.23%
• 5 days: 2.21%
• 1 month: 2.78%
• 3 months: 77.4%
• 6 months: 138.05%
• Year to date: 44.37%
• 1 year: 37.47%
• 5 years: 1.33%
• 10 years: -97.58%
• Sector: Healthcare
• Industry: Biotechnology

About: Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.

Employees: 78